Modern renal transplantation: Present challenges and future prospects

Postgraduate Medical Journal

Volumn 85, Issue 1000, 2009, Pages 91-101

  Galliford, J ^a   Game, D S ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CIPROFLOXACIN; CORTICOSTEROID; COTRIMOXAZOLE; CYCLOSPORIN A; DACLIZUMAB; DIURETIC AGENT; DOPAMINE; EVEROLIMUS; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISOLONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VANCOMYCIN;

ANTICOAGULATION; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DIFFERENTIAL DIAGNOSIS; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG PROTEIN BINDING; DYSLIPIDEMIA; FEMALE FERTILITY; FLUID BALANCE; FOLLOW UP; GINGIVA DISEASE; GRAFT DYSFUNCTION; GRAFT INFECTION; GRAFT RECIPIENT; GUM HYPERTROPHY; HEMATOLOGIC MALIGNANCY; HIRSUTISM; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LAPAROSCOPIC SURGERY; LIVING DONOR; LYMPHOCELE; MYCOSIS; NEPHRECTOMY; ORGAN DONOR; OVARY POLYCYSTIC DISEASE; PNEUMOCYSTOSIS; PREGNANCY; PREOPERATIVE CARE; PROTEINURIA; RECURRENT DISEASE; REVIEW; SOLID TUMOR; SURGICAL TECHNIQUE; TESTIS ATROPHY; URINALYSIS; WOUND HEALING; WOUND INFECTION;

CARDIOVASCULAR DISEASES; FEMALE; FORECASTING; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LIVING DONORS; MEDICAL HISTORY TAKING; NEOPLASMS; ORGAN PRESERVATION; PERIOPERATIVE CARE; PHYSICAL EXAMINATION; PREGNANCY; PREGNANCY COMPLICATIONS; RECURRENCE; TISSUE AND ORGAN PROCUREMENT; TISSUE DONORS; WAITING LISTS;

EID: 63649113349     PISSN: 00325473     EISSN: 14690756     Source Type: Journal    
DOI: 10.1136/pgmj.2008.070862     Document Type: Review

References (82)

1. The Renal Association. UK Renal Registry Tenth Annual Report. Bristol: The Renal Association, 2007.
2. Wight JP, Edwards L, Brazier J, etal. The SF36 as an outcome measure of services for end stage renal failure. Qual Health Care 1998;7:209-21.
3. Van Manen JG, Korevaar JC, Dekker FW, et al. How to adjust for comorbidity in survival studies in ESRD patients: a comparison of different indices. Am J Kidney Dis 2002;40:82-9.
4. Evans RW, Orians CE, Ascher NL. The potential supply of organ donors: an assessment of the efficacy of organ procurement efforts in the United States. JAMA 1992;267:239-46.
5. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725-30.
6. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235-42.
7. Meier-Kriesche HU, Kaplan B. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. Transplantation 2002;74:1377-81.
8. Zelmer JL. The economic burden of end-stage renal disease in Canada. Kidney Int 2007;72:1122-9.
9. Galliford J, Charif R, Chan K, et al. ABO incompatible living renal transplantation with a steroid sparing protocol. Transplantation 2008;86:901-6.
10. Kobayashi K, Censullo ML, Rossman LL, et al. Interventional radiologic management of renal transplant dysfunction: indications, limitations, and technical considerations. Radiographics 2007;27:1109-30.
11. Wong VK, Baker R, Patel J, et al. Renal transplantation to the ovarian vein: a case report. Am J Transplant 2008;8:1064-6.
12. Opelz G, Dohler B. Multicenter analysis of kidney preservation. Transplantation 2007;83:247-53.
13. Balupuri S, Strong A, Hoernich N, et al. Machine perfusion for kidneys: how to do it at minimal cost. Transpl Int 2001;14:103-7.
14. Gok MA, Shenton BK, Buckley PE, et al. Use of thrombolytic streptokinase as a preflush in the NHBD procurement. Transplant Proc 2003;35:769-70.
15. Patel H, Smith RA, Sacks SH, et al. Therapeutic strategy with a membrane-localizing complement regulator to increase the number of usable donor organs after prolonged cold storage. J Am Soc Nephrol 2006;17:1102-11.
16. Bagul A, Hosgood SA, Kaushik M, et al. Carbon monoxide protects against ischemia-reperfusion injury in an experimental model of controlled nonheart beating donor kidney. Transplantation 2008;85:576-81.
17. Bagul A, Hosgood SA, Kaushik M, et al. Effects of erythropoietin on ischaemia/reperfusion injury in a controlled nonheart beating donor kidney model. Transpl Int 2008;21:495-501.
18. Lauschke A, Teichgraber UK, Frei U, et al. 'Low-dose' dopamine worsens renal perfusion in patients with acute renal failure. Kidney Int 2006;69:1669-74.
19. Mehta RL, Pascual MT, Soroko S, et al. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002;288:2547-53.
20. Zacharias M, Gilmore IC, Herbison GP, et al. Interventions for protecting renal function in the perioperative period. Cochrane Database Syst Rev 2005;(3):CD003590.
21. Manikandan R, Sundaram CP. Laparoscopic live-donor nephrectomy. BJU Int 2006;97:1154-60.
22. Pirsch JD, Miller J, Deierhoi MH, et al. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997;63:977-83.
23. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002;73:775-82.
24. National Institute for Clinical Excellence. TA85: Renal transplantation-immuno-suppressive regimens (adults). The clinical effectiveness and cost effectiveness of immuno-suppressive therapy for renal transplantation. London: NICE, 2005.
25. European Mycophenolate Mofetil Cooperative Study Group. Mycophenolate mofetil in renal transplantation: 3-year results from the placebo-controlled trial. Transplantation 1999;68:391-6.
26. Dudley C, Pohanka E, Riad H, et al. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the ''creeping creatinine'' study. Transplantation 2005;79:466-75.
27. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 2000;356:194-202.
28. MacDonald AS. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001;71:271-80.
29. San Juan R, Aguado JM, Lumbreras C, et al. Incidence, clinical characteristics and risk factors of late infection in solid organ transplant recipients: data from the RESITRA study group. Am J Transplant 2007;7:964-71.
30. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant 2006;20:401-9.
31. Campistol JM, Albanell J, Arns W, et al. Use of proliferation signal inhibitors in the management of post-transplant malignancies-clinical guidance. Nephrol Dial Transplant 2007;22(Suppl I):i36-41.
32. Game DS, Hernandes-Fuentes MP, Lechler RI. Everolimus and basiliximab permit suppression by human CD4CD25 cells in vitro. Am J Transplant 2005;5:454-64.
33. Ruggenenti P, Perico N, Gotti E, et al. Sirolimus versus cyclosporine therapy increases circulating regulatory T cells, but does not protect renal transplant patients given alemtuzumab induction from chronic allograft injury. Transplantation 2007;84:956-64.
34. Borrows R, Loucaidou M, Van Tromp J, et al. Steroid sparing with tacrolimus and mycophenolate mofetil in renal transplantation. Am J Transplant 2004;4:1845-51.
35. Webster AC, Playford GE, Higgins G, et al. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomised trials. Transplantation 2004;77:166-76.
36. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004;4:222-30.
37. Bustami RT, Ojo AO, Wolfe RA, et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004;4:87-93.
38. Chan K, Taube D, Galliford J, et al. Randomised controlled trial of Campath and tacrolimus-monotherapy with daclizumab, tacrolimus and mycophenolate mofetil in renal transplantation; interim results. Am J Transplant 2008;8(Suppl 2):216.
39. Briggs JD. Causes of death after renal transplantation. Nephrol Dial Transplant 2001;16:1545-9.
40. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001;72(6 Suppl):S5-8.
41. Matas AJ, Humar A, Gillingham KJ, et al. Five preventable causes of kidney graft loss in the 1990s: a single-center analysis. Kidney Int 2002;62:704-14.
42. Kumar N, Chan K, Baker C, et al. Pre-emptive coronary artery angiography and revascularisation in renal transplant recipients. Renal Association Annual Meeting. Glasgow 2008.
43. Patel RK, Mark PB, Johnston N, et al. Prognostic value of cardiovascular screening in potential renal transplant recipients: a single-center prospective observational study. Am J Transplant 2008;8:1-11.
44. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905-13.
45. Simon DM, Levin S. Infectious complications of solid organ transplantations. Infect Dis Clin North Am 2001;15:521-49.
46. Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008;8:975-83.
47. Myslak M, Amer H, Morales P, et al. Interpreting post-transplant proteinuria in patients with proteinuria pre-transplant. Am J Transplant 2006;6:1660-5.
48. Gloor J, Cosio F, Lager DJ, et al. The spectrum of antibody-mediated renal allograft injury: implications for treatment. Am J Transplant 2008;8:1367-73.
49. Mengel M, Chapman JR, Cosio FG, et al. Protocol biopsies in renal transplantation:insights into patient management and pathogenesis. Am J Transplant 2007;7:512-7.
50. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008;8:753-60.
51. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000;70:887-95.
52. Calne RY. Prope tolerance: the future of organ transplantation-from the laboratory to the clinic. Transplantation 2004;77:930-2.
53. Amer H, Fidler ME, Myslak M, et al. Proteinuria after kidney transplantation, relationship to allograft histology and survival. Am J Transplant 2007;7:2748-56.
54. Prodjosudjadi W, Daha MR, Gerritsma JS, et al. Increased urinary excretion of monocyte chemoattractant protein-1 during acute renal allograft rejection. Nephrol Dial Transplant 1996;11:1096-103.
55. Li B, Hartono C, Ding R, et al. Noninvasive diagnosis of renal-allograft rejection by measurement of messenger RNAfor perforin and granzyme B in urine. N Engl J Med 2001;344:947-54.
56. Muthukumar T, Dadhania D, Ding R, et al. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005;353:2342-51.
57. O'Riordan E, Orlova TN, Podust VN, et al. Characterization of urinary peptide biomarkers of acute rejection in renal allografts. Am J Transplant 2007;7:930-10.
58. Baker RJ, Hernandez-Fuentes MP, Brookes PA, et al. Assessment of the immunological contribution to chronic allograft nephropathy. J Immunol 2001;167:7199-206.
59. Kreijveld E, Koenen HJ, van Cranenbroek B, et al. Immunological monitoring of renal transplant recipients to predict acute allograft rejection following the discontinuation of tacrolimus. PLoS ONE 2008;3:e2711.
60. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: a meta-analysis using an immune function assay. Transplantation 2006;82:663-8.
61. Mueller TF, Einecke G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007;7:2712-22.
62. Sawitzki B, Bushell A, Steger U, et al. Identification of gene markers for the prediction of allograft rejection or permanent acceptance. Am J Transplant 2007;7:1091-102.
63. Game DS, Lechler RI. Pathways of allorecognition: implications for transplantation tolerance. Trans Immunol 2002;10:101-8.
64. Kirk AD. Transplantation tolerance: a look at the nonhuman primate literature in the light of modern tolerance theories. Crit Rev Immunol 1999;19:349-88.
65. Adams AB, Pearson TC, Larsen CP. Heterologous immunity: an overlooked barrier to tolerance. Immunol Rev 2003;196:147-60.
66. Buhler LH, TR S, Sykes M, et al. Induction of kidney allograft tolerance after transient lymphohematopoietic chimerism in patients with multiple myeloma and end-stage renal disease. Transplantation 2002;74:1405-9.
67. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008;358:353-61.
68. Ford ML, Koehn BH, Wagener ME, et al. Antigen-specific precursor frequency impacts T cell proliferation, differentiation, and requirement for costimulation. J Exp Med 2007;204:299-309.
69. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008;21:725-7.
70. Jiang S, Tsang J, Game DS, et al. Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: potential reagents to promote donor-specific transplantation tolerance. Transplantation 2006;82:1738-43.
71. Degauque N, Mariat C, Kenny J, et al. Immunostimulatory Tim-1-specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest 2008;118:735-41.
72. Zheng XX, Gao W, Donskoy E, et al. An antagonist mutant IL-15/Fc promotes transplant tolerance. Transplantation 2006;81:109-16.
73. Lechler RI, Garden OA, Turka LA. The complementary roles of deletion and regulation in transplantation tolerance. Nat Rev Immunol 2003;3:147-58.
74. Kirk AD, Hale DA, Mannon RB, et al. Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003;76:120-9.
75. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005;5:1347-53.
76. Kaufman DB, Leventhal JR, Axelrod D, et al. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am J Transplant 2005;5:2539-48.
77. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005;5:465-74.
78. Knechtle SJ, Pirsch JD, Fechner HJJ, et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003;3:722-30.
79. Ivanyi B. A primer on recurrent and de novo glomerulonephritis in renal allografts. Nat Clin Pract Nephrol 2008;4:446-57.
80. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant 2005;5:1179-85.
81. Hudson BG, Kalluri R, Gunwar S, et al. The pathogenesis of Alport syndrome involves type IV collagen molecules containing the alpha 3(IV) chain: evidence from anti-GBM nephritis after renal transplantation. Kidney Int 1992;42:179-87.
82. Thompson BC, Kingdon EJ, Tuck SM, et al. Pregnancy in renal transplant recipients:the Royal Free Hospital experience. Q J Med 2003;96:837-44.